Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

Rhea-AI Summary

Acrivon Therapeutics (Nasdaq: ACRV) will present preclinical and late-breaking AACR 2026 data showing ACR-368 synergizes with Topo 1 ADC payloads and with PD-L1 blockade, and ACR-2316 plus anti-PD-L1 produced complete, durable tumor regressions in mouse models.

The company noted its AP3 platform guided these combination discoveries; ACR-368 is in a registrational-intent Phase 2b and ACR-2316 is in Phase 1.

Positive

• ACR-368 in registrational-intent Phase 2b
• Fast Track designation for ACR-368 in endometrial cancer
• Breakthrough Device designation for ACR-368 OncoSignature assay
• Preclinical synergy of ACR-368 with Topo 1 ADC payloads
• ACR-2316 plus anti-PD-L1 induced complete durable regressions in mice

Negative

• Key efficacy results are preclinical and limited to mouse models
• ACR-2316 Phase 1 shows mechanism-based neutropenia as an adverse event

Key Figures

AACR meeting dates: April 17–22, 2026 Poster number: 239 Poster number: LB152 +5 more

8 metrics

AACR meeting dates April 17–22, 2026 American Association for Cancer Research Annual Meeting schedule

Poster number 239 ACR-368 + Topo 1 ADC payload synergy poster

Poster number LB152 Late-breaking ACR-368 + PD-L1 blockade synergy poster

Poster number 3789 ACR-2316 + anti‑PD‑L1 complete regression poster

Phase Phase 2b Registrational-intent ACR-368 endometrial cancer study

Phase Phase 1 ACR-2316 WEE1/PKMYT1 inhibitor clinical trial

Current price $1.66 Pre-news trading level on publication day

Market cap $53,643,714 Pre-news equity value based on latest data

Market Reality Check

Price: $1.64 Vol: Volume 1,044,151 is sligh...

normal vol

$1.64 Last Close

Volume Volume 1,044,151 is slightly above 20-day average 972,062, indicating only modest pre-news interest. normal

Technical Shares at 1.66 trade below 200-day MA of 1.73, about 70.62% under the 52-week high 5.6509 and 58.1% above the 52-week low 1.05.

Peers on Argus

ACRV fell 2.35% while peers showed mixed moves: TPST up 0.44%, PSTV down 3.85%, ...

2 Up 1 Down

ACRV fell 2.35% while peers showed mixed moves: TPST up 0.44%, PSTV down 3.85%, RADX down 2.21%, RENB up 19.33%, TELO up 3.05%. Momentum scanner flagged PSTV and CALC up, BRNS down, reinforcing a stock-specific rather than broad sector pattern.

Historical Context

5 past events · Latest: Feb 24 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Conference appearance	Neutral	+0.0%	TD Cowen healthcare conference fireside chat announcement and webcast details.
Feb 23	KOL panel event	Positive	-2.0%	KOL panel and ESGO late-breaking oral on maturing ACR-368 endometrial data.
Feb 18	CLIA lab launch	Positive	-0.6%	Completion and CLIA certification of in‑house lab to support diagnostics.
Jan 23	ESGO oral data	Positive	+1.0%	Announcement of late-breaking oral ACR-368 Phase 2b endometrial data at ESGO.
Jan 08	Pipeline data update	Positive	-34.6%	Positive ACR-368 Phase 2b, initial ACR-2316 data and ACR-6840 CDK11 plans.

Pattern Detected

Recent pipeline-positive or strategic news often saw flat to negative next-day moves, suggesting a tendency for selling or muted reactions even on constructive updates.

Recent Company History

Over the last few months, Acrivon has focused on advancing ACR-368 and ACR-2316, plus its AP3-enabled pipeline. On Jan 8, broadly positive ACR-368/ACR-2316 clinical data and cash runway news coincided with a -34.58% move. Subsequent ESGO-related ACR-368 updates and conference/KOL announcements in late January and February saw small mixed price reactions. The new AACR preclinical combination data fits this ongoing narrative of scientific and clinical progression.

Market Pulse Summary

This announcement highlights preclinical data from Acrivon’s AP3 platform showing strong synergy of ...

Analysis

This announcement highlights preclinical data from Acrivon’s AP3 platform showing strong synergy of ACR-368 and ACR-2316 with ADC payloads and immune checkpoint inhibitors ahead of AACR 2026. It builds on prior positive clinical signals across ACR-368 and ACR-2316 and continued platform expansion. Investors may focus on how future clinical readouts corroborate these findings and on operational milestones such as ongoing Phase 2b and Phase 1 trial progress.

Key Terms

chk1/2, topoisomerase 1, antibody-drug conjugates, wee1/pkmyt1, +4 more

8 terms

chk1/2 medical

"ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent..."

CHK1 and CHK2 are proteins that act like cellular security checkpoints, detecting and helping fix damage to a cell’s DNA so it doesn’t divide with errors. They matter to investors because drugs that block or modify these proteins are being developed to make cancer cells more vulnerable to treatment, so trial results, safety data, or regulatory changes involving CHK1/2 programs can materially affect a biotech company’s value. Think of them as targets for new cancer medicines where success or failure often moves stock prices.

topoisomerase 1 medical

"showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used..."

Topoisomerase 1 is an enzyme that eases twists and tangles in DNA by making a temporary cut in one DNA strand and then resealing it, so cells can copy and read genetic information properly — like a finger untangling a knotted shoelace so it can be used again. It matters to investors because drugs that inhibit or alter this enzyme are important cancer and therapeutic targets; trial results, approvals, or safety issues tied to topoisomerase 1 can materially affect a biotech or pharma company’s prospects and valuation.

antibody-drug conjugates medical

"Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs) ACR-2316..."

A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.

wee1/pkmyt1 medical

"ACR-2316, a WEE1/PKMYT1 inhibitor currently in Phase 1, demonstrated complete..."

Wee1 and PKMYT1 are closely related enzymes that act like brakes on cell division by adding a small chemical tag to CDK1, the protein that tells cells to enter mitosis. Investors watch them because drugs that block these brakes can make fast‑growing cancer cells self‑destruct or increase the effectiveness of other treatments, so clinical results, safety and combination strategies directly affect the commercial value of therapies targeting these enzymes.

pd-l1 medical

"tumor mouse models in combination with anti-PD-L1 checkpoint inhibition WATERTOWN, Mass...."

PD-L1 is a protein found on the surface of some cells that acts like a stop sign for the immune system, telling certain immune cells to back off. It matters to investors because many cancer drugs and diagnostic tests target or measure PD-L1 to unlock immune responses or predict which patients will benefit, affecting clinical success, regulatory approval, and potential sales in the oncology market.

immune checkpoint inhibitors medical

"and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors"

Drugs that release the immune system’s natural “brakes,” allowing immune cells to recognize and attack cancer cells; imagine taking the safety off a guard dog so it can chase intruders. They matter to investors because they can become high-value treatments with large sales potential, but their commercial success depends on clinical trial results, regulatory approval, competition and side-effect management, which all affect a company’s valuation.

fast track designation regulatory

"The company has received Fast Track designation from the Food and Drug Administration..."

A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.

breakthrough device designation regulatory

"The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay..."

A breakthrough device designation is a regulatory program that gives promising medical devices for serious or life‑threatening conditions priority support and faster review from a health authority (e.g., the U.S. FDA). Think of it as a “fast lane” or VIP pass through development and review: it can shorten time to market, lower regulatory uncertainty, and boost a company’s commercial prospects — but it is not an approval by itself.

AI-generated analysis. Not financial advice.

ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs) 

ACR-2316, a WEE1/PKMYT1 inhibitor currently in Phase 1, demonstrated complete and durable tumor regression in immunocompetent, syngeneic tumor mouse models in combination with anti-PD-L1 checkpoint inhibition

WATERTOWN, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced three poster presentations, including one late-breaking presentation, at the upcoming American Association for Cancer Research (AACR) Annual Meeting being held in San Diego, CA from April 17-22, 2026.

“These data further demonstrate our differentiated approach leveraging our AP3 platform to identify therapeutic candidates and combinations with the greatest potential for clinical impact,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and co-founder of Acrivon. “Our data show that a key resistance mechanism to Topo1 inhibitors, the most common ADC payload, is the activation of the CHK1/2 DNA damage repair response, which can be overcome by ACR-368 treatment resulting in synergistic tumor cell killing. We also found that ACR-2316 induced mitochondrial and nuclear genomic damage resulting in activation of the innate and adaptive immune system, leading to complete tumor regression and lasting immune protection in mice when combined with immune checkpoint inhibition.”

Poster Details:

Title	Potent synergy between CHK1/2 inhibitor ACR-368 and the ADC payload topoisomerase 1 inhibitor: Rationale for ADC + ACR-368 combination therapy
Date and Time	Sunday, April 19, 2026; 2:00 p.m. - 5:00 p.m. PT
Session	Experimental and Molecular Therapeutics: DNA Damage and Repair 1
Poster Number	239

Title	ACR-368 synergizes with PD-L1 blockade by coordinated activation of adaptive and innate immunity pathways to achieve robust anti-tumor efficacy
Date and Time	Monday, April 20, 2026; 9:00 a.m. - 12:00 p.m. PT
Session	Late-Breaking Research: Immunology 2
Poster Number	LB152

Title	Treatment with ACR-2316, a potential first- and best-in-class WEE1/PKMYT1 inhibitor, combined with anti-PD-L1 induces complete tumor regression with durable immune memory
Date and Time	Monday, April 20, 2026; 2:00 p.m. - 5:00 p.m. PT
Session	Clinical Research: Combination Immunotherapies
Poster Number	3789

About Acrivon Therapeutics 
Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.

Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment.

In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company’s second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1 trial of ACR-2316 is advancing, with weekly dosing regimens established. Initial data has shown a favorable tolerability profile limited to transient, mechanism-based hematological adverse events, predominantly neutropenia and initial clinical activity across AP3-selected solid tumor types, including PRs in endometrial cancer, as well as SCLC and sqNSCLC, two tumor types which have not shown sensitivity to other clinical WEE1 or PKMYT1 inhibitors currently in development. In addition, the company is advancing ACR-6840, an internally discovered development candidate targeting CDK11.

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our preclinical and clinical results, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.

Investor and Media Contacts:
Adam D. Levy, Ph.D., M.B.A.
alevy@acrivon.com

Alexandra Santos
asantos@wheelhouselsa.com

FAQ

What did Acrivon announce about ACR-368 at AACR 2026 (ACRV)?

Acrivon announced preclinical data showing ACR-368 synergizes with Topo 1 ADC payloads and with PD-L1 blockade. According to Acrivon, these findings derive from AP3-guided studies and support combination strategies moving toward clinical evaluation.

Does ACR-2316 show anti-tumor activity with immune checkpoint inhibitors (ACRV)?

Yes. Acrivon reported ACR-2316 plus anti-PD-L1 produced complete, durable tumor regressions in mice. According to Acrivon, the combination activated innate and adaptive immunity, yielding lasting immune protection in preclinical models.

What clinical status and regulatory designations does ACR-368 have (ACRV)?

ACR-368 is described as being in a registrational-intent Phase 2b for endometrial cancer with Fast Track designation. According to Acrivon, the ACR-368 OncoSignature assay has Breakthrough Device designation from the FDA.

What safety signals have been reported for ACR-2316 in Phase 1 (ACRV)?

Initial Phase 1 data showed a favorable tolerability profile with transient, mechanism-based hematological events, predominantly neutropenia. According to Acrivon, adverse events were mostly transient and consistent with the drug's mechanism.

How did Acrivon use its AP3 platform in these findings (ACRV)?

The company used its AP3 platform to identify pathway-driven combinations and compounds with high clinical potential. According to Acrivon, AP3 produced multimodal proteomics data and predictive insights guiding ACR-368 and ACR-2316 development.

Will the AACR posters for ACR-368 and ACR-2316 be publicly presented and when (ACRV)?

Acrivon will present three posters at AACR 2026, including a late-breaking poster on April 20, 2026. According to Acrivon, sessions occur April 19–20 with poster numbers and scheduled session times published for attendees.